<DOC>
	<DOCNO>NCT00996918</DOCNO>
	<brief_summary>The purpose study ass long-term safety tolerability bapineuzumab subject Alzheimer Disease participate study 3133K1-3000 ( NCT00667810 ) . Over 250 site participate 26 country . Subjects receive bapineuzumab . Each subject 's participation last approximately 4 year .</brief_summary>
	<brief_title>A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Subject complete study 3133K13000 brain magnetic resonance imaging ( MRI ) scan consistent diagnosis Alzheimer Disease MiniMental Status Examination ( MMSE ) &gt; =10 screen Caregiver able attend clinic visit subject Any medical psychiatric contraindication clinically significant abnormality , investigator 's judgment , substantially increase risk associate subject 's participation completion study could preclude evaluation subject 's response . Any significant brain MRI abnormality . Use investigational drug device , bapineuzumab within last 60 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>antibody</keyword>
</DOC>